文献速递小儿麻醉

小儿麻醉中神经肌肉阻滞的使用、监测与拮抗:SPA调查

A Survey of the Society for Pediatric Anesthesia on the Use, Monitoring, and Antagonism of Neuromuscular Blockade.
PubMed 文献 · Anesth Analg · 2021-01-01

该调查向3245名小儿麻醉学会(SPA)成员发放问卷,了解神经肌肉阻滞(NMB)药物使用、监测与拮抗实践。13%回应者中38.9%以舒更葡糖作为主要拮抗剂,≤5年经验者使用更多;仅40%始终进行四个成串刺激监测,38%未告知青春期后女性激素避孕影响。

要点

  • 38.9%回应者以舒更葡糖为主要拮抗剂,25.2%仅使用舒更葡糖。
  • ≤5年经验者更常用舒更葡糖作为主要拮抗剂(OR 2.08,95%CI 1.31-3.31,P=.001)。
  • 仅40%始终进行四个成串刺激监测,且与执业年限呈负相关。

核心结论

  • 舒更葡糖在小儿麻醉中常用,尤其低年资麻醉医生;未告知青春期后女性其激素避孕影响可能导致意外妊娠;培训应强调客观监测NMB。

研究设计与样本

  • 向3245名SPA成员发放问卷,并对75名未回应者随机发送简化随访调查以评估无应答偏倚。

主要发现

  • 初始问卷回应率13%(419/3245);163名(38.9%;95%CI 34.2-43.8)以舒更葡糖为主要拮抗剂,106名(25.2%;95%CI 21.2-30.0)仅使用舒更葡糖。
  • ≤5年经验者较≥6年者更常用舒更葡糖作为主要拮抗剂(OR 2.08;95%CI 1.31-3.31;P=.001),控制机构限制和实践类型后仍显著(aOR 2.20;95%CI 1.38-3.54;P=.001)。
  • 仅40%始终进行四个成串刺激监测,使用与执业年限负相关(Spearman ρ=-0.11,P=.04);以舒更葡糖为主要拮抗剂者监测更不常规(OR 0.56;95%CI 0.34-0.90;P=.01)。
  • 52.8%对青春期后女孩使用舒更葡糖,经验较少者更常用(P<.001);38%未与患者和/或家属讨论其对激素避孕的影响,与经验(P=.33)和执业地点(P=.38)无关。
  • 初始与随访调查回应者的人口学或实践回答无显著差异。

临床怎么用

  • 小儿麻醉中舒更葡糖使用普遍,尤其低年资医生,需注意其在小儿中安全有效性尚未确立。
  • 应加强客观NMB监测(四个成串刺激),尤其在使用舒更葡糖时。
  • 对青春期后女性使用舒更葡糖前,应告知激素避孕影响及围术期意外妊娠风险。

局限性

  • 问卷回应率仅13%,可能存在无应答偏倚;随访调查样本量小(n=75)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the package insert clearly states that "the safety and efficacy of sugammadex in pediatric patients have not been established," we hypothesized that sugammadex is used widely in pediatric anesthetic practice supplanting neostigmine as the primary drug for antagonizing neuromuscular blockade (NMB). Additionally, we sought to identify the determinants by which pediatric anesthesiologists choose reversal agents and if and how they assess NMB in their practice. Finally, because of sugammadex's effects on hormonal contraception, we sought to determine whether pediatric anesthesiologists counseled postmenarchal patients on the need for additional or alternative forms of contraception and the risk of unintended pregnancy in the perioperative period. METHODS: We e-mailed a questionnaire to all 3245 members of the Society of Pediatric Anesthesia (SPA) requesting demographic data and attitudes regarding use of NMB agents, monitoring, and antagonism practices. To address low initial response rates and quantify nonresponse bias, we sent a shortened follow-up survey to a randomly selected subsample (n = 75) of SPA members who did not initially respond. Response differences between the 2 cohorts were determined. RESULTS: Initial questionnaire response rate was 13% (419 of 3245). Overall, 163 respondents (38.9%; 95% confidence interval [CI], 34.2-43.8) used sugammadex as their primary reversal agent, and 106 (25.2%; 95% CI, 21.2-30.0) used it exclusively. Respondents with ≤5 years of practice used sugammadex as their primary reversal agent more often than those with ≥6 years of practice (odds ratio [OR]: 2.08; 95% CI, 1.31-3.31; P = .001). This increased utilization remained after controlling for institutional restriction and practice type (adjusted OR [aOR]: 2.20; 95% CI, 1.38-3.54; P = .001). Only 40% of practitioners always assess NMB (train-of-four), and use was inversely correlated with years of practice (Spearman ρ = -0.11, P = .04). Anesthesiologists who primarily used sugammadex assess NMB less routinely (OR: 0.56; 95% CI, 0.34-0.90; P = .01). A slim majority (52.8%) used sugammadex for pediatric postmenarchal girls; those with less experience used it more commonly (P < .001). Thirty-eight percent did not discuss its effects on hormonal contraception with the patient and/or family, independent of anesthesiologist experience (P = .33) and practice location (P = .38). No significant differences were seen in demographics or practice responses between initial and follow-up survey respondents. CONCLUSIONS: Sugammadex is commonly used in pediatric anesthesia, particularly among anesthesiologists with fewer years of practice. Failure to warn postmenarchal adolescents of its consequences may result in unintended pregnancies. Finally, pediatric anesthesia training programs should emphasize objective monitoring of NMB, particularly with sugammadex use.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Faulk DJ, Austin TM, Thomas JJ, et al. A Survey of the Society for Pediatric Anesthesia on the Use, Monitoring, and Antagonism of Neuromuscular Blockade. Anesth Analg. 2021. PMID: 33543867. doi:10.1213/ANE.0000000000005386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。